

YIM

YOUNG INVESTIGATORS MEETING

IS GOING VIR(TU)AL

from 22nd to 23rd of September 2020



<https://www.pres.eu/pres2020/young-investigators.html>

YIM ORGANIZING COMMITTEE

Chair:

Lovro Lamot, Zagreb, Croatia;

Other Members:

Ezgi Deniz Batu, Ankara, Turkey;

Sarka Fingerhutova, Prague, Czech Republic;

Sonia Melo Gomes, London, UK;

Victoria Harbottle, Newcastle upon Tyne, UK;

Raquel Marques, Lisbon, Portugal;

Erdal Sag, Ankara, Turkey;

Eve Smith, Liverpool, UK;

Contact:

emerge.pres@gmail.com

<https://www.facebook.com/PreSEMERGE>

<https://twitter.com/PreSEMERGE>

YIM 2020 programme

DAY 1

13:30-14:00 --- Opening ceremony (talks without QA)

- 13:30-13:35 Prof Berent Prakken (5 mins)
- 13:35-13:40 Prof Angelo Ravelli (5 mins)
- 13:40-14:00 EMERGE YIM committee welcome and update on initiatives (20 mins)

14:00-14:50 --- *SESSION I - JIA* 10 lightning talks (3 mins+2mins QA)

MODERATORS:

Peter Nigrovic (USA), Brian Feldman (Canada), Gabriele Simonini (Italy), Erdal Sag (Turkey)

14:00-14:05 EARLY ACHIEVEMENT OF JADAS ACCEPTABLE DISEASE ACTIVITY IS STRONGLY PREDICTIVE OF ONE-YEAR REMISSION IN ETANERCEPT-TREATED POLYARTICULAR JIA PATIENTS: RESULTS FROM A BIKER COHORT – **Giulia Armaroli (Germany)**

14:05-14:10 SYNOVIAL TISSUE RESIDENT MEMORY T CELLS MEDIATE ARTHRITIS FLARES – **Margaret Chang (USA)**

14:10-14:15 EXAMINING HEALTH OUTCOMES IN JUVENILE IDIOPATHIC ARTHRITIS- A GENETIC EPIDEMIOLOGY STUDY – **Sarah Clarke (UK)**

14:15-14:20 PATIENT-REPORTED ADVERSE EVENTS AND TREATMENT ADHERENCE IN JIA: ANALYSIS OF TWO LARGE INTERNATIONAL COHORTS – **Alessandra Alongi (Italy)**

14:20-14:25 AN ACTIVE PRONGF/P75NTR AXIS IN ARTHRITIS PATIENTS INFLUENCES CYTOKINE PRODUCTION IN SYNOVIAL FIBROBLASTS – **Luciapia Farina (Italy)**

14:25-14:30 VALIDITY AND RELIABILITY OF FOUR PARENT/PATIENT REPORTED OUTCOME MEASURES FOR JUVENILE IDIOPATHIC ARTHRITIS – **Chiara Trincianti (Italy)**

14:30-14:35 EVALUATION OF ANTI-HBS AND ANTI-VZV ANTIBODY LEVELS IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS TREATED WITH CLASSICAL DISEASE MODIFYING DRUGS AND BIOLOGICS – **Sumeyra Ozdemir Cicek (Turkey)**

14:35-14:40 ROLES OF INTESTINAL BARRIER AND MICROBE-ASSOCIATED MOLECULAR PATTERNS IN THE PATHOGENESIS OF INFLAMMATORY ARTHRITIS – **Julie Poline (France)**

14:40-14:45 CLINICAL OUTCOMES OF JUVENILE ARTHRITIS IN ADULTHOOD: A SYSTEMATIC REVIEW – **Yushi Wang (Canada)**



14:45-14:50 PREDICTING THE INDIVIDUAL RISK OF UVEITIS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: AN INTERNATIONAL MULTICENTER COHORT STUDY – **Joeri van Straalen (Netherlands)**

14:50-15:00 --- Coffee break

15:00-15:40 --- **SESSION II** - Keynote Speakers (15min + 5min QA)

MODERATORS:

Angelo Ravelli (Italy), Marija Jelusic (Croatia), Lovro Lamot (Croatia)

- 15:00-15:20 Ross Petty, Canada
- 15:20-15:40 Patricia Woo, UK

15:40-16:25 --- **e-Poster viewing I** 15 e-posters per parallel session x5 sessions (3mins 3 slides e-posters) *see the table below*

16:25-16:40 --- Coffee break

16:40-17:25 --- **SESSION III - JIA, AID** 9 lightning talks (3 mins+2mins QA)

MODERATORS:

Erkan Demirkaya (Canada), Alexandre Belot (France), Sonia Melo Gomes (UK)

16:40-16:45 EARLY TREATMENT AND IL1RN SNPS AFFECT RESPONSE TO ANAKINRA IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – **Marianna Nicoletta Rossi (Italy)**

16:45-16:50 LONG-TERM SAFETY PROFILE OF ANAKINRA IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – **Gabriella Giancane (Italy)**

16:50-16:55 EARLY START OF BIOLOGICAL TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS: DOES A THERAPEUTIC WINDOW EXIST IN REAL LIFE? – **Antía Garcia Fernandez (Spain)**

16:55-17:00 SHOULD ETANERCEPT BE AVOIDED IN CERTAIN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS DUE TO RISK OF DEVELOPING INFLAMMATORY BOWEL DISEASE? – **Roline Krol (Netherlands)**

17:00-17:05 BASELINE CHARACTERISTICS OF AN INTERNATIONAL LONGITUDINAL COHORT OF 1012 FMF PATIENTS FROM THE EUROFEVER REGISTRY – **Marta Bustaffa (Italy)**

17:05-17:10 PATIENTS WITH PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS AND ADENITIS (PFAPA) SYNDROME HAVE DIFFERENTIAL METHYLATION IN INTRON REGIONS OF PIK3AP1 AND SPON2 GENES – **Ema Lovšin (Slovenia)**

17:10-17:15 THE LEVEL OF INTERFERON ALPHA PROTEIN IN DISTINCT INTERFERONOPATHIES PROVIDES CLUES TO THE OBSERVED DIFFERENTIAL TISSUE INVOLVEMENT – **Lorenzo Lodi (France)**

17:15-17:20 GUT MICROBIOTA PROFILING OF CHILDREN AFFECTED BY CHRONIC NONBACTERIAL OSTEOMYELITIS (CNO): A POTENTIAL ROLE IN THE PATHOGENESIS – **Martina Capponi (Italy)**

17:20-17:25 CLINICAL FEATURES AND OUTCOMES IN STING-ASSOCIATED VASCULOPATHY WITH ONSET IN INFANCY (SAVI) – **Sofia Torreggiani (Italy)**

17:30 - 18:10 --- Session IV - Updates on other groups (talks without QA)

MODERATORS:

Seza Ozen (Turkey), Mercedes Chan (Canada), Eve Smith (UK)

- 17:30-17:40 The pediatric global musculoskeletal task force – Helen Foster (Malaysia/UK) (10 mins)
- 17:40-17:50 ENCA – Wendy Costello, Ireland (10 mins)
- 17.50-18:00 EMEUNET – Felice Rivellese, UK/Italy (10 mins)
- 18:00-18.10 CARRA – Kaveh Ardalan & Sabrina A Gmuca, USA (10 mins)

18:15-19:15 --- Networking (LIVE)*

See below for the instructions

DAY 2

08:30-09:00 ---Emerge Meeting (LIVE)

09:00-09:45---SESSION V - JSLE, JDM 9 lightning talks (3 mins+2minsQA)

MODERATORS:

Christian Hedrich (UK), Jordi Anton (Spain), Sarka Fingerhutova (Czech Republic)

09:00-09:05 LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IS ASSOCIATED WITH REDUCED FLARE FREQUENCY AND DAMAGE ACCRUAL IN CHILDREN WITH JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS – **Eve Smith (UK)**

09:05-09:10 INTERFERON- γ DRIVES THE EXPRESSION OF T-BET IN NAÏVE B CELLS OF PATIENTS WITH PAEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS – **Emiliano Marasco (Italy)**

09:10-09:15 THE PERFORMANCES OF DIFFERENT CLASSIFICATION CRITERIA IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS – **Ezgi Deniz Batu (Turkey)**

09:15-09:20 SEX DIFFERENCES IN JUVENILE-ONSET SLE SUSCEPTIBILITY AND CARDIOVASCULAR RISK COULD BE ASSOCIATED WITH ALTERED TREG PHENOTYPE AND LIPOPROTEIN METABOLISM – **George Robinson (UK)**



09:20-09:25 MEDICATION UTILIZATION AND RENAL BIOPSY PATTERNS IN CHILDHOOD-ONSET LUPUS NEPHRITIS IN THE CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE REGISTRY – **Emily Smitherman (USA)**

09:25-09:30 VALIDATION OF THE EULAR/ACR 2017 IDIOPATHIC INFLAMMATORY MYOPATHY CLASSIFICATION CRITERIA IN JDM PATIENTS – **Erdal Sag (Turkey)**

09:30-09:35 BIOMARKERS GALECTIN-9 AND CXCL10 ARE OF ADDITIONAL VALUE IN THE CLINICAL DECISION-MAKING IN JUVENILE DERMATOMYOSITIS – **Saskia Veldkamp (Netherlands)**

09:35-09:40 ALTERED METABOLISM IN JUVENILE DERMATOMYOSITIS (JDM) MONOCYTES: A NEW THERAPEUTIC FOCUS IN JUVENILE DERMATOMYOSITIS – **Meredyth Wilkinson (UK)**

09:40-09:45 SIGLEC-1 EXPRESSION REFLECTS THE INTERFERON SIGNATURE IN JUVENILE DERMATOMYOSITIS AND DEFINES SUBCLASSES OF PATIENTS WITH DISTINCT INFLAMMATORY AND CLINICAL PROFILES – **Butsabong Lerkvaleekul (Netherlands)**

09:45-10:00 --- *Coffee break*

10:00-10:50 --- **SESSION VI - MISCELLANEOUS** 10 lightning talks (3 mins+2minsQA)
MODERATORS:
Fabrizio de Benedetti (Italy), Natasa Toplak (Slovenia), Ezgi Deniz Batu (Turkey)

10:00-10:05 INTERNET AND SMARTPHONE-BASED ECOLOGICAL MOMENTARY ASSESSMENT AND PERSONALIZED TREATMENT ADVICE (PROFEEL) IN ADOLESCENTS WITH CHRONIC CONDITIONS: A FEASIBILITY STUDY – **Merel Nap-van der Vlist (Netherlands)**

10:05-10:10 CLUSTER CONSORTIUM CHAMPIONS, AND THE IMPORTANCE OF PATIENT AND PARENT INVOLVEMENT AND ENGAGEMENT IN RESEARCH CONSORTIUMS – **Fatjon Dekaj (UK)**

10:10-10:15 UTILIZATION OF ANTI-NUCLEAR ANTIBODY ANALYSIS IN TERTIARY PEDIATRIC CLINIC – **Nihal Sahin (Turkey)**

10:15-10:20 RHEUMATIC DISEASES IN MEXICAN CHILDREN AND THEIR PSYCHOSOCIAL AND ECONOMIC IMPACT ON CAREGIVERS – **Fernando Garcia Rodriguez (Mexico)**

10:20-10:25 IN VITRO ANALYSIS OF STANDARD OF CARE DRUGS ON THE IFN TYPE I SIGNATURE; ASPIRIN AND HYDROXYCHLOROQUINE THE OLD KIDS ON THE BLOCK – **M. Javad Wahadat (Netherlands)**

10:25-10:30 CELL DAMAGE AND PATHOGEN-ASSOCIATED TLR4 LIGANDS FUNDAMENTALLY DIFFER IN THEIR ABILITY TO INDUCE TYPE I INTERFERON EXPRESSION – **Monika Helena Tedy (Germany)**

10:30-10:35 A NATIONAL MULTICENTRE STUDY ON SEVERE PAEDIATRIC RECURRENT IDIOPATHIC PERICARDITIS TREATED WITH IL-1 BLOCKERS: APPROPRIATENESS OF THE STANDARD OF CARE AND PROS AND CONS OF ANTI-IL-1 TREATMENTS. – **Roberta Caorsi (Italy)**

10:35-10:40 COMPARISON OF IVIG RESISTANCE PREDICTIVE MODELS IN KAWASAKI DISEASE – **Ummusen Kaya Akca (Turkey)**

10:40-10:45 ISCHEMIC STROKE IN CHILDREN WITH SCLERODERMA EN COUPE DE SABRE – **Maria Pavlova (Russian Federation)**

10:45-10:50 RAYNAUD'S PHENOMENON IN CHILDREN: A SURVEY OF UK & IRELAND PRACTICE – **Catriona Anderson (UK)**

10:50-11:00 *Coffee break*

10:50-11:30

Voting for best presentations**

See below for the instructions

11:00-11:30 ---- Session VII - Allied health professionals (AHP) presentations (talks without QA)

MODERATORS:

Pavla Dolezalova (Czech Republic), Sylvia Kamphius (Netherlands), Victoria Harbottle (UK)

- **11:00-11:20--- Practical Management of Young People with Chronic Pain – Sue Maillard, UK (20 mins)**
- **11:20-11:30--- Capturing the voice of young people with persistent pain in qualitative research – Rhiannon Joslin, UK (10 mins)**

11:30-12:15 --- e-Poster viewing II 15 e-posters per parallel session x5 sessions (3mins 3 slides e-posters) *see the table below*

12:15-12:30 --- Closing remarks and announcement of the prize winners (LIVE)

E-POSTER VIEWING

E-POSTER VIEWING I, GROUP 1- JIA	
MODERATORS: Christoph Kessel (Germany), Bas Vastert (Netherlands)	
	22/09/2020 15:40-16:25
SOME ASPECTS OF THE PSYCHOEMOTIONAL STATE OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS.	Anna Yuryevna Spivakovskaya
DETERMINANTS OF DISCORDANCE BETWEEN CRITERIA FOR INACTIVE DISEASE AND LOW DISEASE ACTIVITY IN JUVENILE IDIOPATHIC ARTHRITIS	Gabriella Giancane
INFLUENZA VACCINE UPTAKE AMONG JUVENILE IDIOPATHIC ARTHRITIS(JIA) PATIENTS: A MULTI-CENTRE CROSS-SECTIONAL STUDY	Foteini Dasoula
RENAL OUTCOMES OF A COHORT OF PAEDIATRIC PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS	Maria Francesca Gicchino
ECHOCARDIOGRAPHIC FINDINGS OF CHILDREN WITH JUVENILE SPONDYLOARTHROPATHIES	Mehmet Yildiz
SYNOVIAL FLUID NEUTROPHILS FROM PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS DISPLAY A HYPERACTIVATED PHENOTYPE	Mieke Metzemaekers
BIOMARKERS PREDICTING THE FURTHER DISEASE COURSE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA): RESULTS FROM THE INCEPTION COHORT OF NEWLY DIAGNOSED PATIENTS WITH JIA (ICON-JIA)	Margarita Ganeva
SCREENING FOR ANTITHYROID ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTRE EXPERIENCE FROM SOUTHERN ITALY	Roberta Naddei
WHICH MUSCULOSKELETAL SITES INVOLVED CAN WE EXPECT AT JUVENILE IDIOPATHIC ARTHRITIS (JIA) ONSET?	Giusyda Tarantino
COMBINING AGE AT JIA ONSET, FEMALE GENDER, ANA POSITIVITY AND FAMILY HISTORY OF AUTOIMMUNE DISEASE TO PREDICT AUTOIMMUNE THYROID DISEASE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS	Laurie Baas
HOW DO NOT TO MISS THE SYSTEMIC LUPUS ERYTHEMATOSUS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: PRELIMINARY RESULTS OF A RETROSPECTIVE STUDY.	Anastasiya Kupreeva
ESTABLISHMENT OF A REGISTRY FOR JUVENILE IDIOPATHIC ARTHRITIS PATIENTS IN SOUTH AUSTRALIA: FOCUS ON PATIENT-REPORTED OUTCOME AND EXPERIENCE MEASURES (PROMS/PREMS)	Ming Min
POSSIBLE ROLE OF EARLY-LIFE EXPOSURES AND ENVIRONMENTAL RISK FACTORS IN JUVENILE IDIOPATHIC ARTHRITIS	Oya Koker Turan
A FAMILY HISTORY OF AUTOIMMUNITY IS A RISK FACTOR FOR CELIAC DISEASE AND JUVENILE IDIOPATHIC ARTHRITIS CO-OCCURRENCE	Roberta Naddei
A LARGE PROPORTION OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS UNDERGO ANTIBIOTIC TREATMENT AND ARTHROTOMY AT THE ONSET OF DISEASE.	Marion Thomas

E-POSTER VIEWING I, GROUP 2- Autoinflammatory diseases MODERATORS: Ivona Aksentijevich (USA), Andrea Taddio (Italy)	22/09/2020 15:40-16:25
EVALUATION OF THE NEW CLASSIFICATION CRITERIA FOR PFAPA SYNDROME	Athina Fouriki
EVALUATION OF THE THYROID DISORDERS IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER	Mehmet Yıldız
GALECTIN-3: A NEW BIOMARKER FOR DIFFERENTIATING PFAPA (PERIODIC FEVER, ADENITIS, PHARYNGITIS, APHTHOUS STOMATITIS) SYNDROME FROM FAMILIAL MEDITERRANEAN FEVER	Ezgi Deniz Batu
DEVELOPMENT OF AN APP FOR THE MANAGEMENT OF AUTOINFLAMMATORY DISEASES USING AN INNOVATIVE PATIENTS-CLINICIANS CODESIGN APPROACH	Silvia Federici
NOVEL MUTATION IN PSME4 INVOLVED IN PROTEASOME-ASSOCIATED-AUTOINFLAMMATORY-SYNDROME	Carl Christoph Goetzke
OCULAR INFLAMMATORY DISEASES IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER: A TRUE ASSOCIATION OR A COINCIDENCE?	Pinar Ozge Avar-Aydin
MOLECULAR AND CLINICAL FINDINGS IN CHILDREN WITH UNDIFFERENTIATED PERIODIC FEVER SYNDROMES	Zoya Korobova
PATIENTS PERSPECTIVES ON LIVING WITH A SYSTEMIC AUTOINFLAMMATORY DISEASE: IMPACT ON QUALITY OF LIFE	Mariana Correia Marques
PRESENCE OF R202Q MUTATION OF THE MEFV GENE DEFINES AN ATYPICAL SUBTYPE OF PFAPA WHICH BENEFITS FROM COLCHICINE TREATMENT	Maria Elisabetta Pinto
THE UTILITY OF A NEXT GENERATION SEQUENCING PANEL IN DIAGNOSING SYSTEMIC AUTOINFLAMMATORY DISEASES IN INDIA - A SINGLE CENTRE EXPERIENCE	Pallavi Pimpale Chavan
THE MUSCULOSKELETAL SYSTEM MANIFESTATIONS IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER	Betül Sözeri
CONTRIBUTION OF THE NEXT GENERATION SEQUENCING TECHNIQUE IN THE MANAGEMENT OF FAMILIAL MEDITERRANEAN FEVER PATIENTS	Vasiliki Sgouropoulou
MRI AS A DIAGNOSTIC TOOL IN PROTRACTED FEBRILE MYALGIA	Neta Hana Aviran
NLRP1-ASSOCIATED AUTOINFLAMMATION WITH ARTHRITIS AND DYSKERATOSIS (NAIAD SYNDROME) IN A 3-YEAR-OLD BOY	Hatice Adiguzel Dundar



E-POSTER VIEWING I, GROUP 3- COVID-19	
MODERATORS: Chris Scott (South Africa), Grant Schulert (USA)	
	22/09/2020 15:40-16:25
HOW THE COVID-19 PANDEMIC HAS INFLUENCED PEDIATRIC RHEUMATOLOGY PRACTICE: RESULTS OF A GLOBAL, CROSS-SECTIONAL, ONLINE SURVEY	Ezgi Deniz Batu
PAEDIATRIC MULTI-SYSTEM INFLAMMATORY SYNDROME TEMPORALLY ASSOCIATED WITH SARS-COV-2 MIMICKING KAWASAKI DISEASE (KAWA-COVID-19): A MULTICENTRE COHORT	Isabelle Melki
THE COV-ASAKI SURVEY FROM THE PEDIATRIC TUSCANY NETWORK DURING COVID-19 ERA	Maria Vincenza Mastrolia
THE IMPACT OF COVID 19 ON A SPANISH PEDIATRIC RHEUMATOLOGY UNIT: PATIENT-REPORTED OUTCOMES (PRO) UTILITY	Jaime Arroyo Palomo
COVID-19 IN PEDIATRIC RHEUMATOLOGY PATIENTS TREATED WITH BIOLOGIC DRUGS: A CROSS-SECTIONAL, PATIENT SURVEY STUDY	Müşerref Kasap Cuceoglu
ACRAL ERYTHEMATOUS/CYANOTIC LESIONS ASSOCIATED WITH VESSELS ARCHITECTURE DISTORTION DEFINE A NEW CLINICAL ENTITY DURING COVID19 PANDEMIC	Andrea Catzola
PSYCHOSOCIAL IMPACT OF SARS COV-2 OUTBREAK ON PATIENTS WITH PEDIATRIC ONSET SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR CAREGIVERS	Himanshi Chaudhary
SYSTEMIC JIA, KAWASAKI SYNDROME AND MACROPHAGE ACTIVATION, WHAT ELSE? NOT ONLY COVID-19.	Rawane Dagher
A META-ANALYSIS OF SEX BIAS IN COVID-19	Hannah Peckham
ACRAL LESIONS IN A PEDIATRIC COHORT DURING COVID-19 EPIDEMIC	Francesca Orlando
KAWASAKI DISEASE DURING COVID-19 EPIDEMIC	Francesca Orlando
A SURVEY TO UNDERSTAND THE FEELINGS TOWARDS AND IMPACT OF COVID-19 ON THE HOUSEHOLDS OF JUVENILE DERMATOMYOSITIS (JDM) PATIENTS FROM A PARENT OR CARER PERSPECTIVE	Meredyth Wilkinson

E-POSTER VIEWING I, GROUP 4- Treatment of JIA	
MODERATORS: Sefi Uzeil (Israel), Claudia Bracaglia (Italy)	
22/09/2020	15:40-16:25
EVALUATION OF FLARE RATE AND TAPERING STRATEGIES IN JUVENILE IDIOPATHIC ARTHRITIS	Antía García Fernández
EFFICACY OF PULSE DEXAMETHASONE IN ADDITION TO STANDARD THERAPY VERSUS STANDARD THERAPY ALONE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL	Umang Bhardwaj
METHOTREXATE RESPONSE SUBGROUPS IDENTIFIED IN TWO UK JUVENILE IDIOPATHIC ARTHRITIS COHORTS	Stephanie J W Shoop-Worrall
SWITCHING FROM REFERENCE TO BIOSIMILARS DOES NOT REDUCE EFFICACY AND SAFETY IN JUVENILE IDIOPATHIC ARTHRITIS	Ilaria Maccora
ADALIMUMAB TROUGH CONCENTRATIONS ARE ASSOCIATED WITH TREATMENT RESPONSE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS	Martijn Doeleman
ATTAINMENT OF INACTIVE DISEASE FOLLOWING DISCONTINUATION OF ADALIMUMAB MONOTHERAPY IN PATIENTS WITH ERA	Stayroula Papailiou
A REAL-LIFE STUDY OF EFFECTIVENESS AND TOLERABILITY OF ADALIMUMAB BIOSIMILAR IN JIA-A SINGLE CENTRE EXPERIENCE	Varvara Choida
RATES OF PSORIASIS DE-NOVO IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS PRECEDING ANTI-TNF THERAPY: A SINGLE-CENTER OBSERVATIONAL STUDY	Nadezhda Tsurikova
THE POSSIBILITY OF INCREASING THE INTERVALS BETWEEN INJECTIONS OF TNF-ALFA INHIBITORS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTER OBSERVATIONAL STUDY	Nadezhda Tsurikova
ACHIEVING INACTIVE DISEASE IN ERA WITH SECUKINUMAB FOLLOWING TNF INHIBITOR FAILURE; A REAL-LIFE, DUAL-CENTER EXPERIENCE	Stayroula Papailiou
BIOLOGICAL THERAPIES IN JUVENILE IDIOPATHIC ARTHRITIS: ARE THERE ANY DIFFERENCES BETWEEN CATEGORIES?	Antía García Fernández
EFFECT OF DOSE AND DURATION OF GLUCOCORTICOID TREATMENT ON PROGNOSIS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS	Sumeyra Ozdemir Cicek
DERMATOLOGIC ADVERSE EVENTS ASSOCIATED WITH JUVENILE IDIOPATHIC ARTHRITIS TREATMENT	Jade Smorenburg
THE RANGE OF BIOLOGICAL DRUGS USED IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS, SARATOV REGION EXAMPLE.	Anna Yuryevna Spivakovskaya
THE 15-YEAR EVOLUTION OF JIA BIOLOGIC THERAPY PATTERNS IN THE CZECH REPUBLIC	Nikol Vinšová

E-POSTER VIEWING I, GROUP 5- Miscellaneous		22/09/2020
MODERATORS: Raju Khubchandani (India), Linda Hiraki (Canada)		15:40-16:25
PRELIMINARY EVALUATION OF OUR NEWLY LAUNCHED SUB-SPECIALTY PEDIATRICS E CASE SERIES (SPECS) TO INCREASE PEDIATRICIANS' WATCHFULNESS REGARDING UNTOUCHED DISEASES IN CHILDREN IN AN INDIAN STATE OF GUJARAT		Devang B Pandya
GENETIC SYNDROMES MIMICKING RHEUMATOLOGIC DISEASES		Ummusen Kaya Akca
PEDIATRIC SJÖGREN SYNDROME: AN ITALIAN CASE SERIES		Micol Romano
THE MUSCULOSKELETAL MANIFESTATIONS OF SCURVY: A DIAGNOSTIC CHALLENGE FOR THE RHEUMATOLOGIST		Roberta Naddei
CAN ARTIFICIAL INTELLIGENCE HELP WITH DIAGNOSING GROWING PAIN?		Ezgi Deniz Batu
COST SAVINGS SWITCHING FROM INTRAVENOUS (IV) TO SUBCUTANEOUS (SC) TOCILIZUMAB IN THE IRISH NATIONAL CENTRE FOR PAEDIATRIC RHEUMATOLOGY		Ciara Lang
A NEED TO TRAIN PAEDIATRIC RHEUMATOLOGISTS IN MUSCULOSKELETAL ULTRASOUND SCANNING. HOW DO WE MOVE FORWARD?		Fatemeh Jenabi
TREATING TWO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA PATIENTS WITH INTERLEUKIN-1 INHIBITORS		Ruby Haviv
INFLAMMATORY ARTHRITIS COMPLICATING GALACTOSIALIDOSIS : A CASE REPORT AND REVIEW OF THE LITERATURE		Floris Verkuil
HYPERSENSITIVITY REACTIONS WITH DMARDS		Müşerref Kasap Cuceoglu

E-POSTER VIEWING II, GROUP 1- JIA		23/09/2020
MODERATORS: Berent Prakken (Netherlands), Alessandro Consolaro (Italy)		11:30-12:15
VACCINATION COVERAGE IN A COHORT OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTRE EXPERIENCE		Andrea Catzola
MINIMAL SEDATION/ANXIOLYSIS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS UNDERGOING INTRARTICULAR INJECTION OF CORTICOSTEROIDS		Silvia Maria Orsi
SLCO1B1 RS4149056 VARIANT AS THE PREDICTOR OF METHOTREXATE – RELATED GASTROINTESTINAL TOXICITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS		Justyna Roszkiewicz
ESTIMATION OF THE VITAMIN D STATUS AND ITS CORRELATION WITH CLINICAL ACTIVITY IN CHILDREN WITH JIA		Yulia Vyzhga
MUSCULOSKELETAL COMPLAINTS OF CHILDREN WITH PSORIASIS AND ULTRASONOGRAPHIC EVALUATION OF SUBCLINICAL ACHILLES ENTHESOPATHY		Nuray Aktay Ayaz
EARLY REGISTRATION OF MYOCARDIAL DISORDERS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS USING THE 4TH GENERATION ELECTROCARDIOGRAPHY		Agar Artsymovych
CROSS-SECTIONAL STUDY OF FECAL CALPROTECTIN IN CHILDREN WITH VARIOUS FORMS OF ARTHRITIS AND NON-INFLAMMATORY MUSCULOSKELETAL DISORDERS: A SINGLE CENTRE EXPERIENCE		Lovro Lamot
COXARTHROSIS RISK FACTORS IN SYSTEMIC AND NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS.		Lubov Sorokina
OBESITY IMPAIRS ACHIEVEMENT OF CLINICAL INACTIVE DISEASE (CID) IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA) TREATED WITH TNF INHIBITORS		Fabio Basta
PATTERNS AND RATE OF CONFIRMED TRANSITION TO ADULT CARE OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA) AT A TERTIARY PAEDIATRIC RHEUMATOLOGY CENTRE.		Joachim Ju Chin Tan
COMPARISON OF CLINICAL AND ULTRASONOGRAPHIC EVALUATIONS IN JUVENILE IDIOPATHIC ARTHRITIS.		Nora Bogdanova
WHEN RHEUMATOLOGY AND GENETICS MEET: A CASE OF JUVENILE IDIOPATHIC ARTHRITIS IN A PATIENT CARRYING 18Q DELETION.		Maria Francesca Gicchino
THE COMPARISON OF THE HLA-B27-POSITIVE AND HLA-B27-NEGATIVE PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN THE SINGLE CENTER		Rinat Raupov
SUCCESSFUL HAPLO-IDENTICAL ALLOGENIC BONE MARROW TRANSPLANTATION IN A CHILD WITH REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS		Guillaume Morelle

E-POSTER VIEWING II, GROUP 2- Autoinflammatory diseases, uveitis	
MODERATORS: Marco Gattorno (Italy), Joost Swart (Netherlands)	
23/09/2020 11:30-12:15	
A RARE RHEUMATOLOGICAL CAUSE OF DEATH SECONDARY TO AORTIC CALCIFICATION: A CASE REPORT OF SINGLETON-MERTEN SYNDROME	Fiona Elisabeth Price-Kuehne
EARLY DIAGNOSIS OF THE AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS)/ALPS-LIKE SYNDROME IN PATIENTS WITH UNDEFINED AUTOINFLAMMATORY OR AUTOIMMUNE DISORDERS: A MULTIVARIATE ANALYSIS APPROACH IN A PEDIATRIC RHEUMATOLOGY TERTIARY CENTER	Caterina Matucci Cerinic
CORRELATION OF A WHOLE-BODY MRI DERIVED RADIOLOGICAL ACTIVITY INDEX WITH DISEASE ACTIVITY IN CHRONIC NONBACTERIAL OSTEOMYELITIS	Martina Capponi
AN ITALIAN COHORT OF PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS	Micol Romano
A MULTI-CENTRE SERVICE EVALUATION OF ACCESS TO CARE FOR CHILDREN DIAGNOSED WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS IN THE UK	Eve Roberts
GENETICS OF CHRONIC NONBACTERIAL OSTEOMYELITIS IN THE IRISH POPULATION: NO EVIDENCE OF A ROLE FOR FBLIM1 VARIANTS	Daire O'leary
MAJEED SYNDROME AND FMF IN A LEBANESE PATIENT: A CASE REPORT	Rawane Dagher
BROADENING THE GENETIC AND CLINICAL SPECTRUM OF A20 HAPLOINSUFFICIENCY	Andrea Uva
THE CYTOKINE PROFILE IN THE PATIENTS WITH CHRONIC NON-BACTERIAL OSTEOMYELITIS, JUVENILE IDIOPATHIC ARTHRITIS, INSULIN-DEPENDENT DIABETES MELITUS AND HEALTHY CONTROLS: THE DATA OF PROSPECTIVE COHORT STUDY	Maria Makhova
ASSESSING S100 PROTEINS AND CYTOKINES IN TEARS AS POTENTIAL BIOMARKERS FOR UVEITIS DIAGNOSIS AND ACTIVITY IN JIA PATIENTS	Jackeline Rodriguez-Smith
MORBIDITY OF JIA-ASSOCIATED UVEITIS: HALF OF PATIENTS DESPITE SYSTEMIC TREATMENT STILL SHOW OCULAR DAMAGE DURING A LONG-TERM FOLLOW-UP	Gisella Beatrice Beretta
THE CLINICAL FEATURES OF UVEITIS DE-NOVO IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS DEVELOPED ON BIOLOGIC TREATMENT	Marta Chakhalian
TO TAPER OR NOT TO TAPER IN JUVENILE IDIOPATHIC ARTHRITIS: IS THERE A RISK OF DEVELOPMENT OF UVEITIS FLARES?	Maria Andreina Teran
CHANGING EVIDENCE OVER TIME: UPDATED META-ANALYSIS REGARDING ANTI-TNF EFFICACY IN CHILDHOOD CHRONIC UVEITIS	Ilaria Maccora

E-POSTER VIEWING II, GROUP 3- Vasculitis, MAS	
MODERATORS: Fatma Dedeoglu (Turkey), Clare Pain (UK)	
	23/09/2020 11:30-12:15
DIFFERENT HISTOLOGICAL CLASSIFICATIONS FOR HENOCHE-SCHÖNLEIN PURPURA NEPHRITIS - WHICH ONE IS THE BEST PREDICTOR OF DISEASE OUTCOME? PILOT STUDY OF THE PRES VASCULITIS WORKING PARTY	Mario Sestan
A PILOT PROTEOMIC ANALYSIS OF PLASMA BIOMARKERS IN IGA VASCULITIS	Selcan Demir
PREDICTIVE BIOMARKERS OF I IGA VASCULITIS WITH NEPHRITIS BY METABOLOMIC ANALYSIS	Selcan Demir
SPATIAL ANALYSIS OF CHILDHOOD IGA-VASCULITIS IN CROATIA – A PILOT STUDY	Mario Sestan
SYSTEMATIC REVIEW OF CHILDHOOD-ONSET POLYARTERITIS NODOSA AND DADA2	Müşerref Kasap Cuceoglu
CAN WE PREDICT CORONARY ARTERY INVOLVEMENT IN KAWASAKI DISEASE?	Ummusen Kaya Akca
GASTROINTESTINAL MANIFESTATIONS AND THEIR ASSOCIATION WITH THE RISK FOR RENAL DISEASE IN PATIENTS WITH HENOCHE-SCHÖNLEIN'S PURPURA	Mario Sestan
KAWASAKI DISEASE COMPLICATED BY MACROPHAGE ACTIVATION SYNDROME AND PARVOVIRUS B19 INFECTION: WHICH RELATIONSHIP?	Giorgia Martini
SPECTRUM OF VASCULITIS IN 27 CHILDREN FROM A SINGLE CENTER IN AN INDIAN STATE OF GUJARAT	Devang B Pandya
LONG TERM OUTCOME OF POST-VARICELLA ARTERIOPATHY IN CHILDREN	Sara Signa
PERFORMANCE OF THE “MS-SCORE” AND “HSCORE” IN THE DIAGNOSIS OF MAS IN SYSTEMIC JIA PATIENTS	Erdal Sag
TRADITIONAL LABORATORY PARAMETERS AND NEW BIOMARKERS IN MACROPHAGE ACTIVATION SYNDROME (MAS) AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH)	Arianna De Matteis
LIFE-THREATENING MACROPHAGE ACTIVATION SYNDROME WITH FULMINANT MYOCARDITIS SUCCESSFULLY RESCUED BY HIGH DOSE INTRAVENOUS ANAKINRA	Alessandra Meneghel

E-POSTER VIEWING II, GROUP 4- JSLE, inflammatory myopathies		23/09/2020
MODERATORS: Tadej Avcin (Slovenia), Klaus Tenbrock (Germany)		11:30-12:15
VALIDATION OF THE 2019 ACR/EULAR CLASSIFICATION CRITERIA OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A MEXICAN PEDIATRIC POPULATION		Richard Eduardo Loor
'IT GIVES THE TREATMENT STRUCTURE': PATIENT AND PARENTAL PERSPECTIVES ON TREATING TO TARGET IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS TREAT		Eve Smith
RELIABLE DETECTION OF SUBTYPES OF NAILFOLD CAPILLARY HAEMORRHAGES IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS		Sandy C Bergkamp
LUPUS MANIFESTATIONS IN CHILDREN WITH PRIMARY IMMUNODEFICIENCY DISEASES: PHENOTYPIC AND GENETIC FEATURES AND OUTCOME		Hajar Alreefi
OFATUMUMAB USE IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTRE EXPERIENCE		Ovgu Kul Cinar
NEUROLOGICAL MANIFESTATIONS OF PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS		Yasser Gazar
THE USE OF 'THE LUPUS CHECKLIST' IN CONSULTATIONS WITH PAEDIATRIC PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN IMPROVING PATIENT MONITORING OUTCOMES		Kate Amy Alexander
BICKERSTAFF ENCEPHALITIS WITH OVERLAPPING GUILLAIN-BARRÉ SYNDROME AS A FIRST MANIFESTATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT		Aikaterini Koryllou
SPECTRUM OF CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS CLINICAL COURSE		Patricia Morán Álvarez
OVERLAP SYNDROME OF IDIOPATHIC INFLAMMATORY MYOPATHY WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING WITH MACROPHAGE ACTIVATION SYNDROME		Raquel Lopes de Bragança
INVESTIGATING NOVEL MECHANISMS OF T CELLS IN THE PATHOGENESIS OF JUVENILE DERMATOMYOSITIS		Lucy Rachel Marshall
CLINICAL FEATURES, MUSCLE BIOPSY SCORES, MYOSITIS SPECIFIC ANTIBODY PROFILES AND OUTCOME OF JDM PATIENTS		Erdal Sag
USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY MYOPATHIES OF CHILDHOOD		Giulia Camilla Varnier
EVALUATION OF DISEASE ACTIVITY IN CHILDREN WITH JUVENILE DERMATOMYOSITIS: A COMPARISON BETWEEN ELECTROMYOGRAPHY AND WHOLE BODY-MAGNETIC RESONANCE IMAGING		Simone Carbogno

E-POSTER VIEWING II, GROUP 5- Miscellaneous	
MODERATORS: Jelena Vojinovic (Serbia), Raquel Marques (Portugal)	
	23/09/2020 11:30-12:15
TRANSITION READINESS ASSESSMENT FROM PEDIATRIC TO ADULT SERVICES IN RHEUMATIC DISEASES	Sirinthip Kittivisuit
PSYCHOLOGICAL INVOLVEMENT IN YOUNG PEOPLE WITH CHRONIC RHEUMATOLOGICAL DISEASE: WHAT INPUT DO PATIENTS NEED?	Olufunmilola Ogundiran
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RHEUMATOLOGIC DISEASES: THE EXPERIENCE OF A THIRD-LEVEL HOSPITAL IN MEXICO.	Sandra Rodríguez Aguayo
NEUTRALIZING ANTI-RITUXIMAB ANTIBODIES IN CHILDREN WITH IMMUNE MEDIATED DISEASES	Ilja Oomen
PERICARDIAL EFFUSION AFTER CARDIAC SURGERY: RETROSPECTIVE STUDY IN A PEDIATRIC COHORT.	Camilla Celani
MULTIDISCIPLINARY AND SYSTEMATIC CARE MODEL OF A TRANSITIONAL RHEUMATIC CLINIC IN MEXICO	Sol Jiménez Hernández
A SCOPING REVIEW TO SUPPORT THE DEVELOPMENT OF PGALSPLUS: A MULTI-PROFESSIONAL TOOL AND RESOURCE	Vicky Mercer
A NOVEL MULTIDIMENSIONAL ASSESSMENT TOOL FOR CLINICAL CARE OF PATIENTS WITH JUVENILE FIBROMYALGIA SYNDROME	Enrico Drago
"DESCRIPTION OF THE CHARACTERISTICS OF THE NAILFOLD CAPILLARY STRUCTURE IN HEALTHY CHILDREN: A PILOT STUDY	Hatice Adiguzel Dundar
METHOTREXATE INTOLERANCE: CHILDREN VS ADULTS	Ummusen Kaya Akca
A SYSTEMATIC REVIEW EXPLORING THE BIDIRECTIONAL RELATIONSHIP BETWEEN PUBERTY AND AUTOIMMUNE RHEUMATIC DISEASES	Nina Maria de Gruijter
ANTI-ADALIMUMAB ANTIBODIES DETECTION USING A NOVEL PEPTIDE-BASED ASSAY IN A COHORT OF PEDIATRIC PATIENTS WITH CHRONIC RHEUMATIC DISORDERS : A PILOT STUDY	Edoardo Marrani



***NETWORKING EVENT:**

This is a social event, so please grab a drink, log on... And join one of the teams. After the initial icebreakers to introduce ourselves, there will be a competition and the winner team will receive a secret prize at the end! Following this you will have the chance to discuss and engage directly with our senior faculty on several topics.

TABLES AT THE NETWORKING EVENT:

TABLE 1:

Eve Smith (UK) + Chris Scott (South Africa) + Grant Schulert (USA) + Andrea Taddio (Italy) + Marija Jelusic (Croatia);

TABLE 2:

Ezgi Deniz Batu (Turkey) + Fabrizio de Benedetti (Italy) + Christian Hedrich (UK) + Jelena Vojinovic (Serbia) + Linda Hiraki (Canada) + Gabriele Simonini (Italy);

TABLE 3:

Sonia Melo Gomes (UK) + Seza Ozen (TURKEY) + Sefi Uziel (Israel) + Marco Gattorno (Italy) + Claudia Bracaglia (Italy) + Patricia Woo (UK);

TABLE 4:

Raquel Marques (Portugal) + Ivona Aksentijevich (USA) + Sue Maillard (UK) + Joost Swart (Netherlands) + Natasa Toplak (Slovenia);

TABLE 5:

Sarka Fingerhutova (Czech Republic) + Raju Khubchandrani (India) + Tadej Avcin (Slovenia) + Clare Pain (UK) + Fatma Dedeoglu (USA);

TABLE 6:

Vic Harbottle (UK) + Berent Prakken (Netherlands) + Pavla Dolezalova (Czech Republic) + Christoph Kessel (Germany) + Erkan Dermikaya (Canada);

TABLE 7:

Erdal Sag (Turkey) + Angelo Ravelli (Italy) + Alexandre Belot (France) + Mercedes Chan (Canada) + Bas Vastert (Netherlands) + Jeannette Cappon (Netherlands);

TABLE 8:

Lovro Lamot (Croatia) + Peter Nigrovic (USA) + Sylvia Kamphuis (Netherlands) + Alessandro Consolaro (Italy) + Klaus Tenbrock (Germany);



****Selection of Prize Winners at virtual YIM meeting 2020:**

1. All e-lightning presentations will be considered for the YIM prizes.
2. There will be one 1st, 2nd and 3rd prize for the best clinical presentation and one for the best basic/translational presentation.
3. Judging for the prize will be a two-stage process:
 - a. All registered attendees of the YIM will be able to vote once for the best clinical and once for the basic/translational e-lightning presentation on **23rd of September between 10.50 and 11.30 CET** at the link that will be available at the congress website;
 - b. The special panel consisting of 3 seniors and 2 EMERGE members will then choose from the top three scored presenters the final winners (1st, 2nd, 3rd for clinical and 1st, 2nd, 3rd for basic science) on the zoom meeting.
4. The YIM attendees and panel members are instructed to watch every presentation and to select the best basic translational and the best clinical presentation according to the following criteria:
 - a. clarity of slides and talk
 - b. adherence to time
 - c. ability to deliver message
 - d. background and information about methods provided to follow the presentation;
 - e. structure of the study and the relevance to clinical practice or development of the field;
5. The panel members are:
 - a. **Sefi Uzeil** (*Tel Aviv, Israel*): pediatric rheumatologist and PReS council Chair for the clinical affairs;
 - b. **Christoph Kesel** (*Munster, Germany*): former YIM prize winner and basic scientist;
 - c. **Gabriele Simonini** (*Florence, Italy*): pediatric rheumatologist and epidemiologist;
 - d. **Sonia Melo Gomes** (*London, UK*): pediatric rheumatologist and EMERGE member;
 - e. **Lovro Lamot** (*Zagreb, Croatia*): pediatric rheumatologist, EMERGE chair and PReS council trainee representative;



6. The prize winners will be announced at the live closing session on **23rd of September between 12.15 and 12.30 CET.**
7. The best clinical and basic/translational e-lightning talks (1st place only) will be shown at the opening ceremony of the main congress, along with other prizes:
 - a. **1st prize:** free registration at PReS annual congress, EUREKA summer school course, or any of the PReS-sponsored courses, basic or advanced, **with** travel (in economy class) and accommodation expenses;
 - b. **2nd & 3rd prize:** free registration at PReS annual congress, EUREAK summer school or any of the PReS-sponsored courses, basic or advanced, **without** the travel and accommodation expenses;
8. All winners will be displayed within the online YIM prize winner's hall of fame at PReS website;